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The PPARs are integral parts of the RXR-dependent signaling networks. Many other nuclear receptor subfamily 1 members also
require RXR as their obligatory heterodimerization partner and they are often co-expressed in any given tissue. Therefore, the
PPARs often complete with other RXR-dependent nuclear receptors and this competition has important biological implications.
Thorough understanding of this cross-talk at the molecular level is crucial to determine the detailed functional roles of the PPARs.
At the level of DNA binding, most RXR heterodimers bind selectively to the well-known “DR1 to 5” DNA response elements.
As a result, many heterodimers share the same DR element and must complete with each other for DNA binding. At the level of
heterodimerization, the partners of RXR share the same RXR dimerization interface. As a result, individual nuclear receptors must
completewitheachotherforRXRtoformfunctionalheterodimers.Cross-talkthroughDNAbindingandRXRheterodimerization
present challenges to the study of these nuclear receptors that cannot be adequately addressed by current experimental approaches.
Novel tools, such as engineered nuclear receptors with altered dimerization properties, are currently being developed. These tools
will enable future studies to dissect speciﬁc RXR heterodimers and their signaling pathways.
Copyright © 2009 L. S. A. Chan and R. A. Wells. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
The PPARs are one of the most studied RXR heterodimer-
ization partners. Over 1000 papers have been published on
the PPARs since their cloning in 1990 [1]. Although some
evidence suggests that the PPARs can form homodimers and
bind to DNA response elements such as the Pal3 motif [2],
it is widely accepted that the PPARs must heterodimerize
with RXR to carry out most of their functions. Therefore,
like other RXR’s partners, the PPARs are integral parts of
the RXR-dependent signaling network—RXR is also the
obligatory heterodimerization partner of at least twenty
mammalian nuclear receptors (NRs) [3–10]. Since studies
in mouse have shown that multiple RXR’s partners are
o f t e nc o e x p r e s s e di na n yg i v e nt i s s u e[ 11–16] (also see
the Nuclear Receptor Signaling Atlas (NURSA) [17]), it
appears that cross-talk between these partners is a com-
mon phenomenon. Cross-talk between these partners is
complex and presents a unique challenge to researchers
who are trying to understand the function of individual
NR.
This paper will focus on the basis of the cross-talks
between RXR’s partners from a molecular biology per-
spective, where these NRs compete against each other for
DNA binding and RXR heterodimerization. In addition, this
paper will discuss the challenges faced by investigators using
current experimental approaches to dissect and understand
the functional role of individual partners of RXR.2 PPAR Research
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Figure 1: (a) Ribbon drawing of the human RXRα/human PPARγ heterodimer on PPRE (PBD 3E00). (b) Ribbon drawing of the
heterodimer/DNA complex showing only the PPRE and the DBDs of RXRα and PPARγ. The RXR and PPAR monomers are colored in
dark and light grey, respectively. The PPRE is colored in black; the 5  and 3  ends are also labeled.
2.How Do RXR HeterodimersBind to Their
DNA Response Elements?
MostRXR/partnerheterodimersrecognizeandbindtodirect
repeat (DR) DNA sequences as their response element [18–
23]. The consensus DR sequence consists of two direct repeat
half-sitesseparatedbyanumberofnucleotides(5 -AGGTCA
n(x) AGGTCA-3 ). A DR separated by a single nucleotide
is referred to as DNA response element direct repeat 1
(DR1). In addition, the sequence of the actual 5 -AGGTCA-
3  half-site varies among diﬀerent response elements. The
RXRα/PPARγ heterodimer preferentially binds to the DR1
PPAR response element (PPRE) [24], and the crystal struc-
ture of this heterodimer/DNA complex is recently reported
(Figure 1)[ 25]. During DNA binding, the heterodimer is
arranged such that the DNA binding domain (DBD) from
each monomer occupies one 5 -AGGTCA-3  half-site. Most
heterodimers are selective toward DR sequences with one
to ﬁve nucleotides spacing (i.e., DR1 to DR5). At the
molecular level, addition or subtraction of a single base
pair between the half-sites imposes a separation of 3.4 ˚ A
and a rotation of 36◦ between the two half-sites [19].
Since a DBD is only slightly longer than one half-site, the
structural conformations required for the heterodimers vary
greatly for diﬀerent DRs. Heterodimerization of the DBDs
on their correct DR elements helps deﬁne the structural
conformation of the heterodimer, which in turn stabilizes
the protein/DNA complex. It is also worth noting that the
RXR DBD is ﬂexible and undergoes structural changes to
accommodate the DBDs from diﬀerent partners.
There are two additional consequences to these DNA
binding properties. First, unlike the inverted repeat DNA
sequence used by other NRs, the DR sequence is asym-
metrical and can only be read correctly from one direction
[26–28]. This restricts the protein complex to bind to the
DNA in only one orientation, in contrast to inverted repeats
Table 1: DR element binding properties of RXR homodimers and
heterodimers.
DR element RXR homo/heterodimer
DR1 RXR- RXR, RAR, PPAR, COUP, HNF4
DR2 RXR-PPAR, RAR
DR3 RXR-VDR
DR4 RXR-TR, LXR, CAR
DR5 RXR-RAR, NGFI-B
or everted repeats, which can interact with their cognate
NR complex in both 5  and 3  orientations. Consequently,
the protein complex exerts its eﬀect in a unidirectional
manner. Second, unlike homodimers, heterodimers can bind
to response elements with RXR occupying either the 5 
upstreamor3  downstreamhalf-site[29–32].Thisdiﬀerence
in polarity eﬀectively doubles the number of possible
RXR/partner heterodimer combinations, even though not
all combinations are capable of DNA binding. In addition,
diﬀerent RXR polarity can result in completely diﬀerent
gene regulatory responses. For instance, although the RXR-
RAR heterodimer binds to both DR1 and DR5, the RXR
monomer occupies the 3  half-site of DR1 and the 5  half-
site for DR5 [30]. This allows ligand-dependent activation
for RXR-RAR heterodimer on DR5, but not on DR1. Hence,
diﬀerent genes can be regulated in diﬀerent manner by
a given heterodimer and ligand. The crystal structure of
RXRα/PPARγ heterodimer on the PPRE reveals that PPARγ
resides upstream of RXRα, resembling the organization of
RXR/RAR on DR1 [25]( Figure 1). However, it is unclear
whether PPARγ can also reside downstream of RXRα and
exert diﬀerent activation properties.
Since there are more than forty heterodimer com-
binations and only ﬁve DR response elements, many
heterodimers share the same DR element (Table 1)[ 19].PPAR Research 3
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Figure 2: (a) Ribbon drawing of the human RXRα LBD homodimer (PBD 1MZN). The RXR monomers are colored in black. The N and
C termini are labeled “N” and “C”, respectively. Rotation of 180◦ on the Z-axis of the homodimer results in a geometry equivalent of the
starting geometry (i.e., C2 symmetry). The I-boxes are colored in light grey. (b) Ribbon drawing of the hRXRα/hPPARγ LBD heterodimers
(PDB 3E00, also see Figure 1). The RXR and PPAR monomers are colored in dark and light grey, respectively.
This implies that diﬀerent heterodimers must compete for
DNA binding. A well-known example is that the RXR
homodimer and several other RXR heterodimers can recog-
nize and bind to the DR1 element [29]. Subsequently, cross-
talk becomes possible among diﬀerent heterodimers and
the signaling pathways they represent. Several mechanisms
exist to control the relative aﬃnity of these dimers to
DR1 [33]. First, the expression level of NRs varies among
diﬀerent cell types; thus, protein abundance may determine
DNA binding [11]. Second, the precise sequence of the
DR element inﬂuences the binding speciﬁcity of diﬀerent
dimers. For instance, the PPREs have a well conserved
AAACT extension sequence located upstream of the DR
site [34]. The crystal structure of RXRα/PPARγ heterodimer
revealed that the hinge region of PPARγ can recognize this
AAACT element and allow speciﬁc PPREs binding [25].
Nevertheless, the speciﬁcity of RXR/PPAR heterodimer to
PPRE does not necessarily preclude DNA binding by other
RXR heterodimers that also recognize the DR1 element.
3.How DoRXR andIts Partners
Form Heterodimers?
Although RXR and its partners may perform certain func-
tions as monomers or homodimers, the heterodimers are
responsible for most gene regulatory activities. Therefore,
it is reasonable to regard the heterodimer as the basic
functional unit of the signaling network, rather than viewing
RXR and its partner monomer as separate units. Numerous
studies have been conducted to investigate the heterodimer-
ization properties of RXR and its partners using X-ray
crystallography and mutational analysis of the amino acid
sequence. Although both the DBD and the ligand binding
domain(LBD)areinvolvedindimerization,theLBDismore
important due to its much larger and stronger dimerization
interface [35, 36]. Therefore, studies on RXR/partner het-
erodimerization have mainly focused on the LBD.
3.1. The Structure of RXR Homo/Heterodimer. The RXR
LBD homodimer (Figure 2(a)) was the ﬁrst RXR dimer
to be resolved by X-ray crystallography [36]. Each RXR
monomer consists of twelve α-helices (H1 to H12) and two
short β-strands (s1 and s2), which are organized in three
layers to form an antiparallel “α-helical sandwich” [37]. The
homodimer has twofold symmetry and forms a rotationally
symmetric dimer. The dimer interface consists of amino
acid residues that are arranged as a hydrophobic cluster sur-
rounded by charged and polar residues. These residues inter-
act with each other to stabilize the homodimer and therefore
are essential for dimerization. The structural arrangement
of the PPAR LBD resembles that of the RXR LBD, except
the PPAR LBD has one extra α-helice and two extra β-
strands [38]. The crystal structures of several RXR/partner
LBD heterodimers have been resolved since the publication
of the RXR LBD homodimer, including RXR/RAR [39, 40],
RXR/CAR [41, 42], RXR/LXR [43, 44], and RXR/PPAR [25,
45–47]. These heterodimers share the same global structure
with the RXR LBD homodimer. Nevertheless, individual
heterodimers have speciﬁc conﬁgurations, which diﬀer from
the RXR homodimer prototype. These diﬀerences include
deviation of a monomer from the symmetry axis, the exact
area that the monomers contribute to the dimer interface,
and the rearrangement of interactions between amino acid
residues from the monomers. For instance, the monomers
of the RXRα/PPARγ LBD heterodimer (Figure 2(b))[ 25]
deviate about 10◦ from the C2 symmetry, which leads to
increased surface contact area between the monomers and
enhances the stability of the heterodimer [45].4 PPAR Research
Since each heterodimer possesses diﬀerent heterodimer-
ization interface, it is reasonable to conjecture that some
partners can form more stable heterodimers with RXR than
can others, even though the relative stability of each het-
erodimer is yet to be fully established. It has been suggested
that the quantity of RXR available for heterodimerization
is limited and under strict control [48, 49]. As a result,
cross-talk between RXR’s partners can be achieved via RXR
sequestration. For instance, the presence of excess LXR or its
ligands reduces DNA binding of PPARα/RXRαto PPRE[50],
which inhibits PPAR signaling and suppresses transcription
of lipid degradation genes. Conversely, excess of PPARα
and its ligands suppresses the sterol regulatory element-
bindingprotein-1cpromoterthatcontainstwoLXRresponse
elements[51].Thisinhibitioncanberelievedbytheaddition
of RXRα, suggesting that competition for and sequestration
of RXR is a contributor to cross-talk between the LXR
and PPAR signaling pathways. Other examples of cross-talks
between RXR’s partners include PPAR with COUP-TF [52],
TR with LXR [53], TR with VDR [54], and multiple partners
(CAR,PXR,LXR,FXR,andPPAR)ontheexpressionofP450
enzymes [55].
3.2. Amino Acid Residues that Are Important in Dimerization.
The dimer interface holds the key to dimerization, and
amino acid residues within this interface are especially
important. Early studies showed that deletion of the RXR
LBD from amino acid position 443 to the C-terminal
end does not disrupt dimerization [56], while additional
deletion to position 433 disrupts RXR homodimerization
but not heterodimerization with other NRs. Further deletion
to position 413 abolishes all dimerization activities. These
observations suggested that a short region of RXR 413-
443 is required for dimerization, and the region 413-433
is particularly important to heterodimerization. Subsequent
analysis by the Evans’ group redeﬁned the heterodimeriza-
tion region as 387-429 and termed this region the “I-box”
[57] (Figures 2 and 3). As observed in the crystal structure,
the I-box lies within helices H9-H10, which is at the center
of the dimer interface. RXR and all of its known partners
possess the I-box, and a number of highly conserved amino
acid residues are found in this region. Interestingly, RAR
acquires the heterodimerization properties of RXR when
its I-box is replaced by that of the RXR, and vice versa
[57].
Mutational analysis of RXR homo- and heterodimer-
ization has also utilized amino acid mutations through
site directed mutagenesis. The results indicated that com-
bination of mutations at the I-box disrupt dimerization,
presumably through steric hindrance or charge conﬂiction
within the dimer interface. For instance, the Pfahl’s group
has reported that simultaneous mutations of L418R, L419S,
and L422Q can completely abolish RXR homo- and het-
erodimerization [56]. In addition, other mutations can alter
heterodimerization of RXR with certain partners. These
mutations include RXR A416D or R421L, which speciﬁcally
disrupt the formation of the RXR/TR heterodimer, and
RXR A416K, which disrupts RXR/RAR and RXR/TR [58].
Likewise, the I-box of the partner of RXR is equally vital
to heterodimerization, such as VDR K382E (equivalent to
human RXRα K417) cannot form heterodimers with RXR
[59]. The I-box may also hold the key that determine RXR
homo-andheterodimerization.TheGronemeyer’sgrouphas
reported that a RXR mutant (Y402A) is able to provide
additional stabilization to the RXR homodimer interface,
making the RXR mutant unavailable for heterodimerization
[35]. Overall, these studies identify the I-box as a crucial
element for RXR heterodimerization, and mutations at this
region can alter heterodimerization properties.
4. Studieson the RXR-Dependent Signaling
Network andIts IndividualPathways
A number of experimental approaches have been employed
to study the function of RXR and its partners, including tar-
geted gene disruption, naturally occurring NR mutants, and
heterodimer speciﬁc ligand stimulation. Studies using these
approaches have contributed greatly to the understanding of
the RXR dependent signaling network. However, there are
limitations and it remains diﬃcult to address the functional
roles of individual heterodimers in isolation.
4.1. Targeted Gene Disruption. Gene knockout models have
been extensively used to characterize the physiological role
of RXRs. RXRα knockout (−/−) in mouse is embryonic
lethal in mid-gestation because of a noncell autonomous
defect in the development of the ventricular myocardium
[60, 61]. It is possible to bypass the embryonic lethality
using tissue speciﬁc conditional knockout [61]. Studies
based on this system suggested that RXRα has an essential
role in multiple pathways including glutathione homeostasis
and detoxiﬁcation of xenobiotics [62], the lifespan and
regenerative capacity of hepatocytes [63], proliferation and
diﬀerentiation of epidermal keratinocytes [64, 65], and
development of prostatic intraepithelial neoplasia [66].
Knockout of PPARγ inmousehasestablisheditsinvolvement
in the development placental, cardiac, and adipose tissue
[67–69], while RARs are involved in spermatogenesis and
fetal development [70, 71]. Observations from these gene
disruption models have helped to establish the physiological
roles of RXR and its partners. However, these models cannot
clearly deﬁne the exact functions of individual heterodimers
because of the unique relationship between RXR and its
partners. First, genes from a particular signaling pathway
can be coregulated by one or more pathways. For instance,
disruption of one RAR isoforms is often compensated by
the other two RAR isoforms [70, 71]. This implies that
the remaining intact pathways can mask the eﬀect of the
knockout by maintaining certain gene regulatory activities
normally handled by the absent partner. Second, the absence
of a partner through targeted gene disruption increases
the availability of RXR and cofactors. Consequently, these
excess proteins can enhance the activities of other intact
heterodimers and their subsequent signaling pathways.
4.2. Heterodimer Speciﬁc Ligand Stimulation. Ligand-
dependent activities of RXR heterodimers are of majorPPAR Research 5
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Figure 3: Amino acid sequences of the I-box region of RXRα, USP, COUP, RARα,T R β, PPAR, and VDR. The I-box lies within Helix 9 (H9)
and helix 10 (H10) (shaded) and has been shown to be essential to dimerization. The amino acid residues equivalent to hRXRα E390 and
K417 are also marked.
interest in NR research due to their physiological relevance
and potential application in medicine. For instance,
thiazolidinediones (TZDs) activate PPARγ in brown
and white adipocyte, and induce the transcription of
PGC-1 alpha. PGC-1 alpha is involved in the control of
mitochondrial biogenesis and has been linked to insulin
sensitization [72]. Other pharmacological compounds
such as WY-14643[73], L-165041 [74], and GW-7845 [75]
are speciﬁc ligands for α, δ,a n dγ isoforms, respectively.
Bisphenol diglycidyl ether (BADGE) [76] and LG100641
[77]a r eP P A R γ selective antagonists, while nonsteroidal
anti-inﬂammatory drugs (NSAIDs) can block PPARδ
speciﬁcally [78]. Nevertheless, a number of heterodimer-
speciﬁc ligands exert eﬀects independent of their receptor.
For instance, PPARγ speciﬁc ligands troglitazone and
15-deoxy-prostaglandin J2 inhibit growth of prostate and
bladder carcinoma cell lines. However, this eﬀect is not
blocked by a PPARγ antagonist [79]. This observation leads
totheconclusionthattheparticulargrowthinhibitioneﬀects
of both agents are mediated through PPARγ independent
mechanisms [79, 80]. Receptor independent eﬀects have also
been reported for RAR ligands [81]. Hence, even though
these eﬀects may be essential to medical and pharmaceutical
applications, they do not contribute to the RXR dependent
signaling network and may create confusion in analyzing
the functions of individual heterodimers. Furthermore,
the use of ligands cannot address the functional role of
apo-heterodimers, which binds to their respective response
element even in the absence of ligand.
4.3. A New Approach to Dissect Individual RXR Signaling
Pathway. TheresearchofRXRdependentsignalingnetworks
requires the precise characterization of individual signaling
pathways. However, current experimental approaches are
insuﬃcient to achieve this objective due to the unique
properties of the signaling network. A novel experimental
system consisting of engineered RXR and partners with
controllable heterodimerization speciﬁcity would be helpful
to complement the existing approaches and to circumvent
their limitations. Our laboratory has created and tested
an engineered RXR/PPAR heterodimer consist of mouse
(a)
(b)
hRXRα hPPARγ
H9 C2 symmetry
H10
X
H10
H9
mRXRα
K422eq
3.51 ˚ A
mPPARγ
E405eq
Figure 4:(a)RibbondrawingofhRXRα/hPPARγ LBDheterodimer
(PDB 3E00, also see Figure 2). (b) The detail view of the equivalent
amino acid sidechains of mouse RXRα K422 and mouse PPARγ
E405. The shortest distance between the negative (side chain
carboxyl group of E405) and positive (side chain amino group of
K422) charges is also displayed.
RXRα K422E and mouse PPARγ E405K mutants [82]. The
creation of these mutants is based on the proposed salt-
bridge between RXRα K422 and PPARγ E405 (Figure 4). In
addition,PPARγ E405andRXRαK422correspondtohuman
RXRα E390 and K417, which are highly conserved among
RXR and its partners in mammalian species (Figure 3).
Since this salt-bridge is located within the heterodimer
interface, we postulate that this salt-bridge may have a role
in heterodimerization. We also hypothesized that reversing
the polarity of the side chains of these amino acids may alter6 PPAR Research
Table 2: Altered heterodimerization properties of the RXR and
PPAR charge-reversal mutants.
RXR PPAR Heterodimer?
Wide-type Wide-type YES
Wide-type E405K YES
K422E Wide-type NO
K422E E405K YES
heterodimerizationspeciﬁcitybutthesalt-bridgewillbekept
intact. Indeed, our observations suggest that the mutant pair
is able to form a heterodimer. Although PPARγ E405K can
form a heterodimer with wild-type RXRα,R X R α K422E is
not able to heterodimerize with wild-type PPARγ (Table 2).
In addition, ligand response of the PPARγ E405K mutant
is comparable to that of the wild-type PPARγ, suggesting
that the general structure of this mutant is preserved. The
restricted heterodimerization capacity of the RXRα K422E
mutant is especially exciting, since the salt-bridge between
RXRα K422 and PPARγ E405 (Figure 4(b)) is predicted to
exist in other RXR’s partners based on the crystal structures
of the LBD heterodimers (RXR/RAR [39, 40], RXR/CAR
[41, 42], RXR/LXR [43, 44], and RXR/PPAR [45–47]).
We are currently conducting experiments to determine if
the restriction on heterodimerization of RXRα K422E is
also applicable to other NR partners, and if mutants of
these partners (equivalent to PPARγ E405K) can restore
heterodimerization with RXRα K422E. If true, our approach
will permit rescue, in the context of RXR knockout, of
speciﬁcNRpathwayeitherbyknock-inorbyinvitrodelivery
of dimerization restricted NR pairs. Expression of RXRα
K422E and PPARγ E405K mutants in RXRα−/− cells could,
for instance, be used to restore speciﬁcally the functions
mediated by RXRα/PPARγ heterodimer, thus identifying the
contribution of this particular heterodimer to the whole
phenotype. Hence, it maybe possible to dissect the RXR-
dependent signaling pathway in a precise manner using
dimerization-restricted NR pairs.
In summary, more than twenty RXR heterodimers share
only ﬁve common DNA response elements. Although some
of these DNA response elements have features that favor
binding by speciﬁc heterodimer, direct competition for DNA
binding is a common phenomenon for these heterodimers.
Competition for RXR among the partners of RXR is also
intense due to the expression of multiple NRs in the
same cell and the limited availability of RXR. There is
evidence suggesting that the relative expression level of
diﬀerent NRs and RXR dictates the activity of individual
NR pathways. Hence, direct competition for DNA binding
and heterodimerization has signiﬁcant roles in the cross-
talk between PPARs and other RXR’s partners. These unique
properties present challenges to the study of these partners.
A novel experimental approach is currently being developed
to alter the dimerization properties of selected heterodimers,
which will allow future studies to dissect a speciﬁc RXR
heterodimer and its signaling pathway from the rest of the
RXR-dependent signaling network.
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